World Health Organization: Addressing Ebola and other Highly Infectious Diseases Internationally

Funding Opportunity Number: CDC-RFA-CK15-1505 Opportunity Category: DiscretionaryFunding Instrument Type: Cooperative AgreementCategory of Funding Activity: HealthCFDA Number: 93.09993.818Eligible Applicants Others (see text field entitled "Additional Information on Eligibility" for clarification)Agency Name: HHS-CDCClosing Date: Jun 29, 2015Award Ceiling: $0Expected Number of Awards: 1Creation Date: Apr 29, 2015Funding Opportunity Description: The Centers for Disease Control and Prevention entered into its current five-year cooperative agreement with the World Health Organization on September 1, 2014. The agreement will end on August 31, 2019. CDC and WHO initiated this cooperative agreement relationship in 1995 as an outgrowth of previous collaborations and as part of the CDC strategy to address emerging infectious diseases. Over the years, these agreements have served as broad-scope umbrella agreements under which a wide variety of projects addressing emerging infectious diseases may be undertaken collaboratively. On September 19, 2011, the Government of the United States of America and the World Health Organization signed a Memorandum of Understanding (MOU) to assist WHO Member States in strengthening their capacity to meet the requirements of the International Health Regulations (2005). The MOU encourages CDC and WHO to pursue activities that improve the abilities of all nations to detect, report, and respond to infectious diseases quickly and ...
Source: - Category: Research Tags: Health Source Type: funding

Related Links:

[Deutsche Welle] Authorities in the Democratic Republic of Congo have started using a second vaccine to fight Ebola. The country is struggling to contain what is now the world's second-worst outbreak of the deadly virus on record.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
This study provides a better understanding of GP expression and processing in BmN cells, which may lay a foundation for EBOV-GP expression using the BmNPV baculovirus expression system.
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Health authorities in eastern Congo have introduced a new Ebola vaccine produced by Johnson&Johnson, aid group MSF said on Thursday, to help combat the world's second-worst outbreak of the virus on record.
Source: Reuters: Health - Category: Consumer Health News Tags: healthNews Source Type: news
The government of the DRC supports use of Janssen ’s vaccine regimen as part of expanded public health response to country’s Ebola outbreak – the second-worst on record
Source: Johnson and Johnson - Category: Pharmaceuticals Source Type: news
This article highlights the epidemiology, clinical features, diagnosis, management, and prevention of EVD. The emerging diagnostic technologies, rapid viral characterization, geospatial mapping of EVD transmission, and new treatments and vaccines are discussed.
Source: Infectious Diseases Clinics of North America - Category: Infectious Diseases Authors: Source Type: research
Darwyn Kobasa Ebola virus (EBOV) is a zoonotic pathogen that poses a significant threat to public health, causing sporadic yet devastating outbreaks that have the potential to spread worldwide, as demonstrated during the 2013–2016 West African outbreak. Mouse models of infection are important tools for the development of therapeutics and vaccines. Exposure of immunocompetent mice to clinical isolates of EBOV is nonlethal; consequently, EBOV requires prior adaptation in mice to cause lethal disease. Until now, the only immunocompetent EBOV mouse model was based on the Mayinga variant, which was isolated in 1...
Source: Viruses - Category: Virology Authors: Tags: Article Source Type: research
Abstract Ebola virus (EBOV) represents a major concern to global health due to the unpredictable nature of outbreaks. Infection with EBOV can cause a severe viral haemorrhagic fever with no licensed vaccine or treatment, restricting work with live EBOV to Containment/Biosafety Level 4 facilities. Whilst the magnitude of recent outbreaks has provided an impetus for vaccine and antiviral development, establishing the efficacy of candidate vaccine materials relies on EBOV challenge models and advanced human trials should outbreaks occur and where logistics and funding allow. To address these hurdles in vaccine develo...
Source: Vaccine - Category: Allergy & Immunology Authors: Tags: Vaccine Source Type: research
Nature, Published online: 21 October 2019; doi:10.1038/d41586-019-03197-wThe World Health Organization says that the rate of new infections in the Democratic Republic of the Congo has dropped, as a vaccine moves closer to approval.
Source: Nature AOP - Category: Research Authors: Source Type: research
New cases are down to 15 a week from a high of 128 in April, but outbreaks are still popping up in remote and dangerous mining areas.
Source: NYT Health - Category: Consumer Health News Authors: Tags: Ebola Virus Epidemics Disasters and Emergencies Vaccination and Immunization World Health Organization Tedros Adhanom Ghebreyesus Congo, Democratic Republic of (Congo-Kinshasa) Uganda Source Type: news
[Vanguard] Health authorities in the Democratic Republic of Congo will introduce a Johnson&Johnson Ebola vaccine in November in the country's eastern provinces, to counter the current outbreak, they said.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news
More News: African Health | Centers for Disease Control and Prevention (CDC) | Ebola | Ebola Vaccine | Epidemiology | Funding | Government | Grants | Health | Infectious Diseases | International Medicine & Public Health | Laboratory Medicine | Outbreaks | Research | Vaccines | WHO